Navigation Links
Purdue Pharma Agrees to Pay $600 Million Fine for Misbranding Oxycontin

US-based Purdue Pharma, makers of painkiller OxyContin agreed to pay $600 million in fines and other payments to resolve the criminal charge of misbranding the product , one of the largest amounts ever paid by a drug company in such a case.

Three of its current and former executives pleaded guilty Thursday to criminal charges that it had misled doctors and patients when it claimed the drug was less likely to be abused than traditional narcotics.

The three executives, including its president and its top lawyer, also pleaded guilty to misdemeanor charges of misbranding the drug. Together, they agreed to pay $34.5 million in fines.

The hearing included statements by numerous people who said their lives were changed forever by the addiction potential of OxyContin, a trade name for a long-acting form of the painkiller oxycodone.

OxyContin is a powerful, long-acting narcotic that provides relief of serious pain for up to 12 hours.

Initially, Purdue Pharma contended that OxyContin, because of its time-release formulation, posed a lower threat of abuse and addiction to patients than traditional, faster-acting painkillers like Percocet or Vicodin.

That claim became the linchpin of an aggressive marketing campaign that helped the company sell over $1 billion worth of OxyContin a year.

Purdue Pharma, based in Stamford, Connecticut, heavily promoted OxyContin to doctors like general practitioners, who often had little training in treating serious pain or in recognizing signs of drug abuse.

But experienced drug abusers and novices, including teenagers, soon discovered that chewing an OxyContin tablet or crushing one and then snorting the powder, or injecting it with a needle produced a high as powerful as heroin.

OxyContin is a pure, high-strength version of a long-used narcotic, oxycodone. By 2000, parts of the United States, particularly rural areas, began to see soaring ra tes of addiction and crime related to use of the drug.

At a news conference Thursday in Roanoke, John L. Brownlee, the United States attorney for the Western District of Virginia, said the impact of Purdues marketing of OxyContin had resulted in rising crime rates, teenage drug addiction, deaths and other problems. The results of Purdues crimes were staggering, he said.

From 1996 to 2001, the number of oxycodone-related deaths nationwide increased fivefold while the annual number of OxyContin prescriptions increased nearly 20-fold, according to a report by the U.S. Drug Enforcement Administration. In 2002, the DEA said the drug caused 146 deaths and contributed to another 318.

U.S. District Judge James Jones in Virginia placed the company on probation for five years and each of the executives on probation for three years. He also ordered the three to perform 400 hours of community service related to prevention of prescription drug abuse.

Jones said he would have preferred to have the plea agreements call for spending money on education of those at risk of drug abuse and treatment of those who are addicted to OxyContin. But Jones said he would not reject the agreement.

"Many young people mistakenly believe today that prescription drugs are safer than other drugs," Jones said.

The fines are to be distributed to state and federal law enforcement agencies, the federal government, federal and state Medicaid programs, a Virginia prescription monitoring program and individuals who had sued the company. About $5 million will go toward a six-year company program to monitor compliance with the agreement.

Survivors of the victims want the Food and Drug Administration to reclassify OxyContin for use only for severe pain. The drug currently can be prescribed for moderate pain.

Purdue has said it accepted responsibility for its employees' actions and has put in place trai ning and monitoring programs to ensure overpromotion of OxyContin doesn't happen again. But officials objected to any ties between the plea agreement and abuse of the drug.

Many of those who gave statements had spoken at a rally before the hearing.

"One of my main infuriations with that company is that for years they denied there was an epidemic," said Ed Bisch of Palm Coast, Fla.

"The first time I heard the word OxyContin was when I was told my 18-year-old son died of an overdose," said Bisch.

Bisch, who has a Web site called www.oxyabusekills.com, drove to the hearing with two other parents, including Lee Nuss, who held up an urn slightly larger than a pill bottle that she said contained her son's ashes.

"I feel you are legal drug users, nothing more than a large corporate drug cartel," Nuss said addressing the Purdue Pharma contingent.

The coal-mining region of southwest Virginia where the sentencing took place has had a number of oxycodone-related deaths -- 119 from 2003 through 2005, according to the state medical examiner's office.

The guilty plea by Purdue Frederick, an affiliate of Purdue Pharma is the latest of a number of cases brought by the Justice Department against pharmaceutical makers that accuse them of misbranding, a broad statute that makes it a crime to put false or misleading information about a drug on its label or in ads, or to promote it for unapproved use.

Some drug industry critics said Thursday that while the fines sent an important message, the amounts were far too low, given the vast profits from OxyContin sales and the problems caused by the drug.

The damage to the public from these white-collared drug pushers surely exceeds the collective damage done by traditional street drug pushers, Dr. Sidney Wolfe, the director of the health research group at Public Citizen, an advocacy group in Washington, said.
Meantime another drug maker Bristol-Myers Squibb has pleaded guilty to making false statements to a federal agency, ending an unusual criminal case involving its blockbuster blood-thinning drug Plavix.

The case involved accusations that the company had entered a secret deal to head off generic competition to Plavix, its biggest-selling product. The investigation began last summer with a search of the companys Manhattan headquarters by federal agents and it led to the dismissal of the chief executive, Peter R. Dolan.


'"/>




Related medicine news :

1. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
2. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
3. Pharma cos must forge Strategic alliances
4. Medicis Pharmaceutical company enters pediatric market
5. Pharma majors gear to supply anti-anthrax drug
6. Pharmacies in for a dose of bitter medicine
7. Andhra Pradesh to set up Pharma City
8. Sun Pharma to launch chiral version of omeprazole soon
9. AAI Pharma Files Lawsuit Against Dr. Reddys Laboratories
10. Pharmacia may take 51.5 percent Abbott stake
11. Pharmaceutical companies are targeting patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/4/2016)... ... , ... Are You Concerned About Mold In Your Home or Workplace? ... Companies in VA, MD and DC, recently completed its application for the new District ... in the district of Columbia is a good thing stated John Taylor, Owner of ...
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and Sara ... speak at the American Conference Institute’s 21st Drug & Medical Device Litigation Conference ... Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device & ...
(Date:12/2/2016)... Los Angeles, CA (PRWEB) , ... December 02, 2016 , ... For over twenty-four years, ... a lien basis to help personal injury victims find high quality medical care. When ... the Los Angeles area. Fast forward to present day and the now ten-page directory ...
(Date:12/2/2016)... ... December 02, 2016 , ... FlexiSpot, ... of its 60-day free trial program for all of the company’s desktop riser ... a truly hassle free experience. , FlexiSpot’s unique desktop risers use an advanced ...
(Date:12/2/2016)... New York, NY (PRWEB) , ... December 02, 2016 , ... ... Through an exclusive interview with Mediaplanet, Dr. Murthy explains how he was inspired to ... “Early on I learned that medicine is about more than making diagnoses and prescribing ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... -- Seno Medical Instruments, Inc., the company pioneering the development ... the process of diagnosing breast cancer, today announced that ... surveillance and clinical follow-up study at the 2016 ... from December 6-10, 2016 at the Henry B. Gonzalez ... . Seno Medical Instruments will present two ...
(Date:12/5/2016)... and TAIPEI, Taiwan , Dec. ... months of treatment ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) ... a significantly better safety and tolerability profile of ropeginterferon alfa-2b ... from PROUD-PV and the ongoing long-term follow-up trial CONTINUATION-PV to ... PharmaEssentia intends to present this data to the FDA ...
(Date:12/4/2016)... 3, 2016 Sickle cell disease (SCD) is ... blood cells that get stuck in veins and block ... failure, and complications leading to death. Each year, approximately ... and most of them lack access to comprehensive care ... long-term therapy for SCD, a pill called hydroxyurea approved ...
Breaking Medicine Technology: